Article Text

other Versions

PDF
Randomised controlled trial
Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment
  1. Ivan Gentile,
  2. Guglielmo Borgia
  1. Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, Italy
  1. Correspondence to: Dr Ivan Gentile, Section of Infectious Diseases (Ed. 18), University of Naples Federico II, via Pansini, 5 I-80131 Naples, Italy; ivan.gentile{at}unina.it

Statistics from Altmetric.com

Commentary on: OpenUrlCrossRefPubMedWeb of Science

Context

Approximately 150 million people worldwide are estimated to be chronic carriers of hepatitis C virus (HCV). Estimates indicate a quarter of HCV carriers will develop liver cirrhosis, which entails a risk of severe complications (hepatocellular carcinoma, decompensation, end-stage liver failure, death).1 Viral clearance significantly decreases disease progression and increases survival rates. Two antiviral approaches are currently available: interferon-based and interferon-free. Interferon-free therapies are the future of HCV treatment thanks to the optimal tolerability and safety, high efficacy and because they can be administered regardless of disease stage and impairment of other systems.2 The only approved interferon-free combination is ribavirin with sofosbuvir, which is indicated for genotype 2 or 3 infection, and for genotype 1 infection in case of …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.